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“It is vain to do with more what can be done with less.”
—William of Occam
In the past few years, we have witnessed a dramatic
proliferation in the use of stents as a treatment for symp-
tomatic coronary artery disease. Stents now account for over
60% of catheter-based coronary interventions in the U.S. In
1998, 500,000 patients were treated with stents (1). Several
factors have contributed to this explosive increase: the
reassuring early results achieved with stenting, leading to a
reduction in the number of emergency bypass operations
and obviating the need for surgical standby (2,3); the
decrease in the incidence of stent thrombosis and bleeding
complications after the procedure with the administration of
antiplatelet therapy (4,5) after the emergence of the key role
of platelets in this complication (6); and the demonstrated
advantage of stenting over plain percutaneous transluminal
coronary angioplasty (PTCA) in terms of restenosis and
restenosis-driven events for an increasing number of indi-
cations (7,8). Despite overwhelming enthusiasm, coronary
stent placement is still an immature technology (9). The
report of Kobayashi et al. (10) in this issue indicates that the
gauging process of stent placement is far from complete.
Before declaring the plain balloon dead and ready to bury
(11) or before calling the balloon back (3) to dethrone the
stent, we need to learn much more about how to improve
the outcome of patients undergoing stent implantation, and
the study of Kobayashi et al. (10) helps to achieve this goal.
See page 651
Choosing the best stent type. The opinion that all stents
are equivalent with respect to the outcome of patients
treated is widely held among interventional cardiologists
(12). The stent is often seen as a simple piece of metal that
serves to keep the vessel open. Especially in Europe, the
operator is offered many stent models. This situation is
clearly reflected in the study of Kobayashi et al. (10) in
which 16 different stent types have been inserted in ;1,000
coronary lesions. Many clinical investigators have been so
skeptical about finding a better stent than the first models,
that the comparative stent versus stent studies were gener-
ally designed on the basis of the equivalency hypothesis.
Experimental findings, however, support the relevance of
stent design in determining the results after insertion of a
stent into arteries (13,14). Clinical data are also accumulat-
ing and show that differences in stent design are translated
into differences in outcome. This was the case not only for
stents with markedly different design such as coil and
slotted-tube stents (15), but also for those with more subtle
differences that belong to the multicellular family (16).
Implanting stents with an unfavorable design may even
offset the known advantages of Palmaz-Schatz stenting over
PTCA, although careful selection of the stent model alone
may be rewarded with a 30% to 50% reduction in the
restenosis rate (16,17).
Choosing the right stent deployment strategy. The stent
deployment strategy used by Kobayashi et al. (10) was based
on high pressure balloon inflation (;17 atm on average);
intravascular ultrasound (IVUS) guidance was used in half
of the cases. High pressure balloon inflation was proposed
by the same investigators (18), embraced by the large
interventional cardiology community and ultimately highly
recommended by the American College of Cardiology
Expert Consensus Document on Coronary Artery Stents
(19). By the end of their study (10), we are informed that
the overall restenosis rate in the 743 lesions angiographically
reinvestigated at six months was 32%. Because high pressure
inflation was the only strategy used in this study, the data
provided do not allow identification of its contribution to
the overall result. In fact, from the beginning, the high
pressure inflation technique was so attractive that it was
adopted without hesitation, even though there was no
strong evidence to support its use. Only recently, in a
randomized trial of patients receiving balloon-expandable
stents of multicellular design, it was found that balloon
inflation with a pressure comparable to that used in the
study of Kobayashi et al. (10) was not associated with any
appreciable benefit, as compared with pressures in the range
of 8 to 13 atm (20). The issue of optimal stent deployment
becomes even more complicated considering that despite
the attractive background and a multitude of investigations
during this decade, the advantages of the IVUS guidance
remain to be proved (19).
Choosing how much to stent. The variability in stent
length of the models available up to a few years ago was very
limited; the 15-mm size was most common. Placement of a
single stent of this length was associated with a reduction in
restenosis in STRESS (STent REStenosis Study), which
only included lesions ,15 mm (8). The situation is com-
pletely different now. Lesions fulfilling the BENESTENT
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(BElgian NEtherlands STENT) (7) and STRESS criteria
(8) represent only a small portion of those currently treated.
Interventionalists are increasingly willing to treat longer and
diffuse narrowings as well as lesions at tandem. Manufac-
turers are offering stents with different lengths that enable
matching the stent with lesion length and vessel anatomy.
For long lesions, the operator has the choice of deploying
multiple short stents or a single long stent. The immediate
results with stenting are impressive. However, longer lesions
and multiple stents are usually associated with a higher risk
of restenosis. During the stent placement procedure in long
coronary lesions, we are all faced with the dilemma: Should
we cover only part of the lesion or the entire lesion with
stent(s)? Should we use a single long stent or multiple short
stents? The study of Kobayashi et al. (10) contributes
significantly in resolving this dilemma.
Long lesions have been associated with an increased risk
of restenosis after PTCA. Hirshfeld et al. (21) found a
restenosis rate of 48.5% after plain angioplasty in lesions
.7 mm in length. Even a higher restenosis rate of 58.3%
emerged from the study of Bourassa et al. (22) after
conventional PTCA of lesions .10 mm in length. Simi-
larly, several studies have shown an increased likelihood of
restenosis after coronary stent placement in long lesions
(23,24). However, the issue of the independent role of
lesion length in the outcome after stenting is more complex
than after PTCA alone. Longer lesions usually need a
longer segment to be covered by the stent. This may require
the placement of more than one stent. Both greater stented
length and a higher number of implanted stents may
increase the risk of restenosis and mask the direct relation
between lesion length and lumen renarrowing after stenting.
Kobayashi et al. (10) assessed the specific role of lesion
length, stented segment length and number of stents in the
outcome of 725 patients after coronary stent placement in
1,090 lesions with a special focus on restenosis. Angio-
graphic follow up at six months was performed in 71% of
the patients. The lesions were subdivided into three groups
according to the length of the stented segment, with about
half of the cases belonging to the group with a stented
segment length #20 mm and the other half almost equally
distributed between the other two groups with a stented
segment length of 21 to 35 mm and .35 mm. A collateral
finding of the study is that the in-hospital outcome of the
group with the longest stented segment was characterized
by a four- to sixfold increase in the risk of stent thrombosis
and in the need for bypass surgery. Fortunately, the overall
incidence of these events in this study group was low, and
the authors also found that the increased risk was confined
to those patients with threatened or abrupt vessel closure
before stenting, thus mitigating possible concerns that the
greater extent of stenting might have been responsible.
At follow-up, the incidence of restenosis (diameter ste-
nosis $50%) was 23.9% in the group with short stented
segments, 34.6% in the group with intermediate stented
length and 47.2% in the group with long stented segments.
Interesting results emerged from various stratified analyses.
The authors showed that the association between stented
segment length and restenosis was also present when the
analysis was restricted to patients who received a single
stent, to patients without coil stents and to patients without
total or subtotal occlusions or acute or threatened vessel
closure. It is interesting to note that even under IVUS
guidance there was a continuous increase of the incidence of
restenosis with the increase in stented segment length.
Several other clinical, angiographic and procedural charac-
teristics were also different among the groups with different
stented lengths. This prompted the authors to perform a
multivariate analysis with the objective of identifying the
independent predictors of restenosis. Only three factors
emerged to be independently correlated with angiographic
restenosis at follow-up: A greater stented segment length
and a smaller vessel size were the most potent risk factors of
restenosis, followed far behind by a greater residual stenosis
immediately after stenting. Of note, long lesions did not
constitute a risk factor for restenosis, nor did multiple
stenting. These data suggest, therefore, that the length of
the stented segment has a substantial influence on restenosis
and that this effect cannot be minimized by the use of a
single long stent instead of multiple shorter stents.
Major effort has been spent to reduce the role of a
multitude of risk factors in human medicine, but replacing
a genuine with an iatrogenic risk factor is not what we are
expected to do. If the unsalutary relation between stented
segment length and restenosis is an inalienable feature of
every stenting procedure, stent skeptics would feel encour-
aged and would more emphatically question the basic
usefulness of stenting. The best answer in this regard is
obviously found in past and future randomized trials. The
careful analysis of Kobayashi et al. (10), along with other
reports on this subject, also provides us with sufficient
information on the circumstances in which this risk factor
metamorphosis occurs and the ways to prevent it. For the
entire group of patients included in the study (10), a mean
stented length of 27.5 mm corresponded to an average
lesion length of 12.6 mm. The discrepancy between stented
and angiographic lesion length recognized by the authors
and illustrated in Figure 2 of the report was not evenly
distributed among the three study groups. Although there
was, on average, only 5.5 mm of stenting in “excess” in the
short stenting group, this excess amounts to 38.5 mm in the
long stenting group. This nonuniform discrepancy could
not be sufficiently explained by differences in the indications
for stenting. We are not provided with data on the potential
existence and extent of postangioplasty dissections. The
authors indicate, however, that the discrepancy may be due
to the frequent use of IVUS, which is able to discern
diseased portions even in segments shown angiographically
to be free of lesions.
In another recent study performed in 2,736 patients with
an 83% six-month angiographic follow-up rate, in whom an
average lesion length of 11.1 mm was covered with a mean
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stent length of 17.8 mm, lesion length and not stented
segment length was independently correlated with resteno-
sis (25). Multiple stenting and stent overlap were among the
other independent risk factors. This study concluded that
when there was good matching of the extent of stenting
with lesion length, lesion length continued to have an
important negative effect on restenosis, and that this effect
can be reduced by avoiding multiple and overlapping stents.
The aforementioned results are in favor of a single long
stent strategy for long lesions and warrant, in turn, specif-
ically designed studies in the future.
The lesson that Kobayashi et al. (10) has imparted is that
the interventionalists should be prepared to sometimes resist
the temptation to use stents on the basis of excellent
immediate results, only. We should handle this device with
care. We should not forget that we are called to palliate the
patient’s symptoms by treating significant stenoses, and we
should recognize the frequently ephemeral nature of coro-
nary tree reconstruction. The fight against atherosclerosis
requires a different, biologic arsenal. A minimal residual
stenosis should be the goal at the diseased site responsible
for the patient’s ischemia and not everywhere that wall
abnormalities and insignificant stenoses can be visualized
angiographically. “Spot” stenting proposed by De Gregorio
et al. (26) and lesion-matched single long stenting are
strategies that should be further tested in patients with long
lesions. The utility of stent placement in long coronary
lesions has not yet been documented. The study of Kobay-
ashi et al. (10) and other studies on this subject are
important for establishing the best stent strategy to pursue
for these lesions before launching the necessary randomized
trials of stent versus PTCA. Otherwise, we run the risk of
comparing a mature PTCA with a still untuned stent
technique. Until then, the best we can do is to follow the
recommendation given in the concluding sentence of the
study: “when stenting is performed, the shortest possible
stent length should be utilized,” and we should not allow
Occam’s razor to become rusty.
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